ECSP23030271A - Variantes de anticuerpos caninos - Google Patents

Variantes de anticuerpos caninos

Info

Publication number
ECSP23030271A
ECSP23030271A ECSENADI202330271A ECDI202330271A ECSP23030271A EC SP23030271 A ECSP23030271 A EC SP23030271A EC SENADI202330271 A ECSENADI202330271 A EC SENADI202330271A EC DI202330271 A ECDI202330271 A EC DI202330271A EC SP23030271 A ECSP23030271 A EC SP23030271A
Authority
EC
Ecuador
Prior art keywords
variants
canine antibodies
canine
antibodies
relates
Prior art date
Application number
ECSENADI202330271A
Other languages
English (en)
Inventor
Henry Luis Campos
Lisa Marie Bergeron
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of ECSP23030271A publication Critical patent/ECSP23030271A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere generalmente a variantes de anticuerpos caninos y usos de estos. Específicamente, la invención se refiere a mutaciones en la región constante del anticuerpo canino para mejorar su semivida y otras características.
ECSENADI202330271A 2020-09-28 2023-04-25 Variantes de anticuerpos caninos ECSP23030271A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063084241P 2020-09-28 2020-09-28

Publications (1)

Publication Number Publication Date
ECSP23030271A true ECSP23030271A (es) 2023-07-31

Family

ID=78599123

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202330271A ECSP23030271A (es) 2020-09-28 2023-04-25 Variantes de anticuerpos caninos

Country Status (17)

Country Link
US (1) US12612454B2 (es)
EP (1) EP4217384A2 (es)
JP (1) JP2023543262A (es)
KR (1) KR20230079148A (es)
CN (1) CN116438196A (es)
AR (1) AR123636A1 (es)
AU (1) AU2021349301A1 (es)
BR (1) BR112023005393A2 (es)
CA (1) CA3194936A1 (es)
CL (2) CL2023000878A1 (es)
CO (1) CO2023004102A2 (es)
EC (1) ECSP23030271A (es)
IL (1) IL301413A (es)
MX (1) MX2023003624A (es)
PE (1) PE20231374A1 (es)
TW (1) TW202229337A (es)
WO (1) WO2022067233A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022020944A2 (pt) * 2020-04-17 2022-12-27 Zoetis Services Llc Variantes de anticorpos caninos
EP4217384A2 (en) 2020-09-28 2023-08-02 Zoetis Services LLC Canine antibody variants
JP2025524441A (ja) * 2022-06-21 2025-07-30 ゾエティス・サービシーズ・エルエルシー イヌ科動物抗体変異体
EP4652197A1 (en) 2023-01-20 2025-11-26 Petmedix Ltd. Therapeutic antibodies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
WO2006031370A2 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
WO2012024650A2 (en) 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JP6629069B2 (ja) 2012-06-06 2020-01-15 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
EP4124624A3 (en) 2013-12-20 2023-05-03 Intervet International B.V. Antibodies against canine pd-1
US20210388053A1 (en) * 2018-10-18 2021-12-16 Kindred Biosciences, Inc. Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use
JP2022513653A (ja) * 2018-11-28 2022-02-09 ブリストル－マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体
CN113227134A (zh) * 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体
SG11202106478UA (en) 2019-01-03 2021-07-29 Invetx Inc Compositions for increasing half-life of a therapeutic agent in canines and methods of use
BR112022020944A2 (pt) * 2020-04-17 2022-12-27 Zoetis Services Llc Variantes de anticorpos caninos
US20220119513A1 (en) 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
EP4217384A2 (en) 2020-09-28 2023-08-02 Zoetis Services LLC Canine antibody variants

Also Published As

Publication number Publication date
CN116438196A (zh) 2023-07-14
CA3194936A1 (en) 2022-03-31
US20240010716A1 (en) 2024-01-11
AU2021349301A1 (en) 2023-08-24
AR123636A1 (es) 2022-12-28
US12612454B2 (en) 2026-04-28
TW202229337A (zh) 2022-08-01
BR112023005393A2 (pt) 2023-04-25
IL301413A (en) 2023-05-01
CL2023000878A1 (es) 2023-10-20
JP2023543262A (ja) 2023-10-13
KR20230079148A (ko) 2023-06-05
PE20231374A1 (es) 2023-09-07
CL2024000628A1 (es) 2024-07-19
WO2022067233A3 (en) 2022-05-27
EP4217384A2 (en) 2023-08-02
WO2022067233A2 (en) 2022-03-31
CO2023004102A2 (es) 2023-04-05
MX2023003624A (es) 2023-04-11

Similar Documents

Publication Publication Date Title
CL2023003377A1 (es) Variantes de anticuerpos caninos
CL2023003376A1 (es) Variantes de anticuerpos felinos
CL2023000878A1 (es) Variantes de anticuerpos caninos
CL2024001519A1 (es) Mutaciones en regiones constantes de anticuerpos felinos.
CL2024001562A1 (es) Mutaciones en regiones constantes de anticuerpos caninos.
CL2024000789A1 (es) Variantes de anticuerpos felinos.
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
CO2023007146A2 (es) Variantes de anticuerpos bovinos
UA120981C2 (uk) Антитіло, що зв'язується з il-8, та його застосування
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
SA523450918B1 (ar) أجسام مضادة للنكتين-4 واستخداماتها
EA201991876A1 (ru) Антитела против фактора d и их применения
PE20230259A1 (es) Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso
CR20240255A (es) Anticuerpo anti-trems y usos del mismo
MX2025002524A (es) Mutantes de anticuerpos equinos
CO2024016060A2 (es) Anticuerpos anti-ly6e, inmunoconjugados y usos de estos